GlassScriptPhysician profile
Erik Nisimblat
NPI 1083707012
$920.92
in general payments reported to CMS, 2019-2025
13 companies · $216 in 2025
The $216 reported for 2025 was more than what 76% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $41.45 · 2021: $49.41 · 2022: $143 · 2023: $105 · 2024: $223 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $543.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $286.47 | 2022-2025 | Azstarys |
| Sanofi Pasteur INC. | $202.98 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $134.24 | 2019-2024 | Jornay Pm |
| Cumberland Pharmaceuticals, INC. | $51.94 | 2019-2022 | |
| Glaxosmithkline, LLC. | $44.20 | 2022 | |
| Pfizer INC. | $38.43 | 2019 | |
| Alk-Abello, INC | $36.09 | 2024-2025 | Odactra, Grastek, Ragwitek |
| Merck Sharp & Dohme LLC | $33.27 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $23.55 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $19.59 | 2024 | Qelbree |
| Tris Pharma INC | $17.49 | 2023 | Dyanavel Xr |
| Phadia US INC. | $16.86 | 2024 | Immunocap |
| Arbor Pharmaceuticals, INC. | $15.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Nisimblat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.